Therefore, unlike the single-target therapy achieved by biological agents, oxymatrine improves psoriasis by altering not only the important IL-17 pathway but also affects the inflammatory pathway, the infection pathway, and the metabolic pathway, achieving multipathway and multitarget therapy. Here, IL17A is linked to psoriasis.